PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care ...

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...

ForSight Robotics secures $125M to advance its robotic surgery platform, targeting cataract procedures and additional ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic ...